An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD

NCT04770545 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

792

Enrollment

INDUSTRY

Sponsor class

Conditions

Geographic Atrophy Secondary to Age-related Macular Degeneration

Interventions

DRUG: PEGCETACOPLAN (APL-2)

Sponsor

Apellis Pharmaceuticals, Inc.